More importantly, our direct analysis using a validation cohort of MYCN-na NB patients and comprising bio-specimens acquired during Dx and at PD after IMCT affirmed the acquisition of RD3 loss in PD after IMCT. The gene discussed is RD3; the disease is neuroblastoma.